Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: An open-label, Phase III study

Authors

John W Sleasman, Duke University School of Medicine
William R Lumry, Allergy & Asthma Specialists
Iftikhar Hussain, Vital Prospects Clinical Research Institute
H James Wedner, Washington University School of Medicine in St. Louis
James B Harris, The South Bend Clinic Center for Research
Kecia L Courtney, Grifols Bioscience Research Group
Elsa Mondou, Grifols Bioscience Research Group
Jiang Lin, Grifols Bioscience Research Group
Mark R Stein, Good Samaritan Medical Center

Journal

Immunotherapy

Publication Date

11-1-2019

Volume

11

Issue

16

First Page

1371

Last Page

1386

Document Type

Open Access Publication

DOI

10.2217/imt-2019-0159

Rights and Permissions

Sleasman JW, Lumry WR, Hussain I, Wedner HJ, Harris JB, Courtney KL, Mondou E, Lin J, Stein MR. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study. Immunotherapy. 2019 Nov;11(16):1371-1386. doi: 10.2217/imt-2019-0159. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. For full bibliographic citation, please refer to the version available at www.futuremedicine.com.

Recommended Citation

Sleasman, John W; Lumry, William R; Hussain, Iftikhar; Wedner, H James; Harris, James B; Courtney, Kecia L; Mondou, Elsa; Lin, Jiang; and Stein, Mark R, "Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: An open-label, Phase III study." Immunotherapy. 11, 16. 1371 - 1386. (2019).
https://digitalcommons.wustl.edu/oa_3/23